<br>含硼介孔二氧化硅纳米颗粒可有效递送和靶向肝癌细胞，用于硼中子捕获疗法,ACS Applied Materials & Interfaces

当前位置： X-MOL 学术 › ACS Appl. Mater. Interfaces › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

含硼介孔二氧化硅纳米颗粒可有效递送和靶向肝癌细胞，用于硼中子捕获疗法
ACS Applied Materials & Interfaces ( IF 8.3 ) Pub Date : 2024-04-30 , DOI: 10.1021/acsami.4c02897
Hongyu Tang _{1,

2} , Zhijie Wang ₂ , Haoyang Hao ₂ , Weixian Luo ₂ , Jingru Yang ₂ , Mengyao Li ₂ , Mingxin Yang ₂ , Ziteng Chen ₂ , Ruyu Yan ₂ , Hao Li ₂ , Fan Hu ₂ , Haojun Liang ₂ , Qiuyang Liu ₂ , Linwen Lv ₂ , Junhui Zhang ₂ , Wenxi Su ₂ , Ranran Chen ₂ , Kui Chen ₂ , Ya-Nan Chang ₂ , Meng Wang ₂ , Lingna Zheng ₂ , Xuesong Feng ₁ , Juan Li ₂ , Gengmei Xing ₂

Affiliation

纳米载体已被全面研究，用于开发硼中子捕获疗法（BNCT）中的新型含硼试剂。我们设计并合成了一种多功能介孔二氧化硅纳米颗粒（MSN）基含硼剂。后者涂有脂质双层（LB），并在表面用SP94肽（SFSIIHTPILPL）修饰为SP94-LB@BA-MSN。后者将硼酸（BA）掺入疏水性介孔中，涂有LB，并在LB上用SP94肽进行修饰。 SP94-LB@BA-MSN增强了纳米界面肿瘤靶向能力，但也防止了药物的过早释放，这对于BNCT至关重要，因为肿瘤部位需要足够的硼含量。 SP94-LB@BA-MSN在HepG-2细胞的BNCT治疗中表现出优异的功效。在荷瘤小鼠的动物研究中，SP94-LB@BA-MSN 在肿瘤部位表现出令人满意的积累。注射后4 h，肿瘤部位硼含量达到40.18±5.41 ppm，分别是硼化苯丙氨酸处理小鼠和BA处理小鼠的8.12和15.51倍。对于硼，肿瘤与正常组织的比率为4.41±1.13，肿瘤与血液的比率为5.92±0.45。这些结果表明，纳米粒子有效地将硼传递到肿瘤部位，同时最大限度地减少在正常组织中的积累。总之，这种复合材料（SP94-LB@BA-MSN）作为含硼递送剂在使用 BNCT 治疗肝细胞癌方面显示出巨大的前景。这些发现凸显了 MSN 在 BNCT 领域的潜力。

"点击查看英文标题和摘要"

Boron-Containing Mesoporous Silica Nanoparticles with Effective Delivery and Targeting of Liver Cancer Cells for Boron Neutron Capture Therapy

Nanocarriers have been researched comprehensively for the development of novel boron-containing agents in boron neutron capture therapy (BNCT). We designed and synthesized a multifunctional mesoporous silica nanoparticle (MSN)-based boron-containing agent. The latter was coated with a lipid bilayer (LB) and decorated with SP94 peptide (SFSIIHTPILPL) on the surface as SP94-LB@BA-MSN. The latter incorporated boric acid (BA) into hydrophobic mesopores, coated with an LB, and modified with SP94 peptide on the LB. SP94-LB@BA-MSN enhanced nano interface tumor-targeting ability but also prevented the premature release of drugs, which is crucial for BNCT because adequate boron content in tumor sites is required. SP94-LB@BA-MSN showed excellent efficacy in the BNCT treatment of HepG-2 cells. In animal studies with tumor-bearing mice, SP94-LB@BA-MSN exhibited a satisfactory accumulation at the tumor site. The boron content reached 40.18 ± 5.41 ppm in the tumor site 4 h after injection, which was 8.12 and 15.51 times higher than those in mice treated with boronated phenylalanine and those treated with BA. For boron, the tumor-to-normal tissue ratio was 4.41 ± 1.13 and the tumor-to-blood ratio was 5.92 ± 0.45. These results indicated that nanoparticles delivered boron to the tumor site effectively while minimizing accumulation in normal tissues. In conclusion, this composite (SP94-LB@BA-MSN) shows great promise as a boron-containing delivery agent for the treatment of hepatocellular carcinoma using BNCT. These findings highlight the potential of MSNs in the field of BNCT.

更新日期：2024-04-30

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南